Morgan Stanley
NGNE icon

Morgan Stanley’s Neurogene NGNE Stock Holding History

Morgan Stanley’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.03M Sell
191,724
-93,515
-33% -$2.57M ﹤0.01% 4096
2026
Q1 		$5.75M Sell
285,239
-85,935
-23% -$1.66M ﹤0.01% 4037
2025
Q4 		$7.65M Sell
371,174
-55,402
-13% -$1.38M ﹤0.01% 3852
2025
Q3 		$7.39M Sell
426,576
-119,027
-22% -$2.39M ﹤0.01% 3819
2025
Q2 		$8.16M Buy
545,603
+259,491
+91% +$4.07M ﹤0.01% 3627
2025
Q1 		$3.35M Sell
286,112
-43,751
-13% -$760K ﹤0.01% 4253
2024
Q4 		$7.54M Sell
329,863
-26,562
-7% -$988K ﹤0.01% 3636
2024
Q3 		$15M Sell
356,425
-26,243
-7% -$1.02M ﹤0.01% 3086
2024
Q2 		$13.9M Sell
382,668
-133,940
-26% -$4.72M ﹤0.01% 3043
2024
Q1 		$26.3M Buy
516,608
+176,629
+52% +$5.9M ﹤0.01% 2396
2023
Q4 		$6.59M Buy
339,979
+313,061
+1,163% +$4.48M ﹤0.01% 3694
2023
Q3 		$425K Sell
26,918
-14,181
-35% -$209K ﹤0.01% 5239
2023
Q2 		$682K Buy
41,099
+16
+0% +$262 ﹤0.01% 5052
2023
Q1 		$575K Buy
41,083
+12,962
+46% +$152K ﹤0.01% 5174
2022
Q4 		$286K Sell
28,121
-1,502
-5% -$15.5K ﹤0.01% 5513
2022
Q3 		$379K Sell
29,623
-1,522
-5% -$31.1K ﹤0.01% 5412
2022
Q2 		$641K Sell
31,145
-2,761
-8% -$67.3K ﹤0.01% 5289
2022
Q1 		$1.27M Buy
33,906
+3,906
+13% +$228K ﹤0.01% 4829
2021
Q4 		$2.89M Buy
30,000
+125
+0.4% +$15.2K ﹤0.01% 4274
2021
Q3 		$4.32M Sell
29,875
-1,675
-5% -$256K ﹤0.01% 3896
2021
Q2 		$5.82M Buy
31,550
+14,266
+83% +$3.16M ﹤0.01% 3624
2021
Q1 		$4.26M Sell
17,284
-4,230
-20% -$1.08M ﹤0.01% 3579
2020
Q4 		$6.07M Buy
21,514
+11,903
+124% +$2.91M ﹤0.01% 3050
2020
Q3 		$2.31M Buy
9,611
+5,893
+158% +$1.43M ﹤0.01% 3536
2020
Q2 		$1.24M Buy
3,718
+610
+20% +$159K ﹤0.01% 4002
2020
Q1 		$707K Buy
3,108
+2,984
+2,406% +$614K ﹤0.01% 4179
2019
Q4 		$31K Buy
124
+25
+25% +$2.49K ﹤0.01% 5988
2019
Q3 		$5K Buy
99
+58
+141% +$3.54K ﹤0.01% 6367
2019
Q2 		$2K Sell
41
-33
-45% -$1.7K ﹤0.01% 6461
2019
Q1 		$4K Buy
74
+36
+95% +$1.82K ﹤0.01% 6358
2018
Q4 		$1K Sell
38
-302
-89% -$14.7K ﹤0.01% 6509
2018
Q3 		$20K Buy
340
+42
+14% +$2.48K ﹤0.01% 6136
2018
Q2 		$16K Sell
298
-4,157
-93% -$1.08M ﹤0.01% 6200
2018
Q1 		$1.25M Buy
4,455
+3,895
+696% +$1.08M ﹤0.01% 4387
2017
Q4 		$131K Sell
560
-227
-29% -$53.2K ﹤0.01% 5559
2017
Q3 		$224K Buy
787
+71
+10% +$20.4K ﹤0.01% 5301
2017
Q2 		$202K Sell
716
-303
-30% -$86.7K ﹤0.01% 5324
2017
Q1 		$340K Sell
1,019
-2,410
-70% -$847K ﹤0.01% 5057
2016
Q4 		$1.13M Buy
3,429
+2,793
+439% +$751K ﹤0.01% 4374
2016
Q3 		$169K Buy
636
+187
+42% +$37.7K ﹤0.01% 5085
2016
Q2 		$60K Sell
449
-2,526
-85% -$402K ﹤0.01% 5463
2016
Q1 		$525K Sell
2,975
-534
-15% -$104K ﹤0.01% 4405
2015
Q4 		$876K Buy
3,509
+3,150
+877% +$829K ﹤0.01% 4158
2015
Q3 		$101K Buy
359
+358
+35,800% +$82.5K ﹤0.01% 5423
2015
Q2 		$0 Sell
1
-33
-97% -$5.02K ﹤0.01% 6712
2015
Q1 		$6K Buy
34
+33
+3,300% +$6.71K ﹤0.01% 6310
2014
Q4 		$0 Buy
+1
New +$142 ﹤0.01% 6631

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Morgan Stanley's NGNE Position: Q2 2026 in Review

Morgan Stanley reduced its Neurogene (NGNE) stake by 33% in Q2 2026, selling an estimated $2.57M and leaving 191,724 shares worth $6.03M. The position accounts for ﹤0.01% of the portfolio, ranked #4096.

Morgan Stanley first reported a position in NGNE in Q4 2014 and has held it in 47 quarters since. The position peaked at $26.3M in Q1 2024. 112 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • Morgan Stanley held 191,724 shares of Neurogene worth $6.03M as of Q2 2026.
  • Morgan Stanley sold 93,515 Neurogene shares in Q2 2026, an estimated $2.57M.
  • Neurogene made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #4096 holding.
  • Morgan Stanley first reported a position in Neurogene in Q4 2014 and has held it in 47 quarters since.
  • Morgan Stanley's Neurogene position peaked at $26.3M in Q1 2024.
  • 112 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.